GB1319216A - 6,9-oxygen bridged erythromycin derivatives - Google Patents
6,9-oxygen bridged erythromycin derivativesInfo
- Publication number
- GB1319216A GB1319216A GB1319216DA GB1319216A GB 1319216 A GB1319216 A GB 1319216A GB 1319216D A GB1319216D A GB 1319216DA GB 1319216 A GB1319216 A GB 1319216A
- Authority
- GB
- United Kingdom
- Prior art keywords
- erythromycin
- hydrogen
- epoxide
- enol ether
- dihydroerythromycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
Abstract
1319216 Erythromycin derivatives ABBOTT LABORATORIES 24 March 1972 14080/72 Heading C2A The invention comprises erythromycin compounds of Formula I wherein R 1 is hydrogen or hydroxy and when R 1 is hydrogen, R 2 and R 3 are each hydrogen or are joined together to form a double bond between the 8 and 9 positions; and when R 1 is OH, R 2 and R 3 are each hydrogen. Specific compounds of Formula I include 8,9-anhydroerythromycin B 6,9-hemiketal in which R 1 is H and R 2 and R 3 are joined to form a double bond, 9-dihydroerythromycin A 6,9-epoxide in which R 1 is OH and R 2 and R 3 are hydrogen, and 9- dihydroerythromycin B 6,9-epoxide. A method of producing erythromycin B enol ether comprises the steps of preparing a solution or suspension of erythromycin B in an anhydrous acid, stirring the mixture of erythromycin B and anhydrous acid for from 1 to 4 hours at a temperature of 20‹ to 30‹ C., removing excess acid at a temperature of less than 60‹ C. and isolating the erythromycin B enol ether. A method of producing 9-dihydro-6,9-epoxide of erythromycin A and B by the action of a hydrogenating agent on the appropriate erythromycin enol ether in the presence of a suitable catalyst is described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1408072 | 1972-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1319216A true GB1319216A (en) | 1973-06-06 |
Family
ID=10034634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1319216D Expired GB1319216A (en) | 1972-03-24 | 1972-03-24 | 6,9-oxygen bridged erythromycin derivatives |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB1319216A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407941B2 (en) | 2003-08-26 | 2008-08-05 | Pfizer, Inc. | N-desmethyl-N-substituted-11-deoxyerythromycin compounds |
-
1972
- 1972-03-24 GB GB1319216D patent/GB1319216A/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407941B2 (en) | 2003-08-26 | 2008-08-05 | Pfizer, Inc. | N-desmethyl-N-substituted-11-deoxyerythromycin compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1429922A (en) | Steroid acetals processes for their manufacture and preparations containing them | |
GB1441101A (en) | Reagents for the assay of cardenolide glycosides and aglycones | |
NL180098C (en) | PROCESS FOR PREPARING VERY PURE TERPHYLIC ACID BY OXYDATION OF P-TOLUALDEHYDE. | |
GB1313646A (en) | Process for producing 3-phenyl pentenals | |
IE39476B1 (en) | 3-hydroxy cephalosporins their ether derivatives and methods for their preparation | |
GB1324152A (en) | Process for the production of alkyl cis-chrysanthemates | |
CH509297A (en) | Progestational and deciduogenic 17alpha-substituted-11 | |
GB1319216A (en) | 6,9-oxygen bridged erythromycin derivatives | |
GB1476992A (en) | 25-hydroxychlorestrol and derivatives thereof | |
US3681326A (en) | 9-substituted erythromycin a and b oximes | |
GB1445707A (en) | Imidazolyl-indane and imidazolyl-tetralin derivatives | |
US3780019A (en) | Production of erythromycylamine compounds | |
GB1311408A (en) | Process for the preparation of butyrolactones | |
GB1412239A (en) | Triiodo-benzoic acid derivatives processes for their production and x-ray contrast compositions including them | |
GB1074491A (en) | Novel processes for preparing steroid compounds, the compounds when thus prepared, novel steroid compounds thereby prepared, and pharmaceutical compositions containing the novel compounds | |
DE2611788A1 (en) | FLUOROPROSTAGLANDINE, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PRODUCTS CONTAINING THEM | |
GB1494940A (en) | Process for the preparation of an octadienenitrile compound | |
GB1315053A (en) | Process for the manufacture of 1,1,2,2,-tetrahydro-perfluoro-alkan ols | |
GB1366664A (en) | 3 - /3 - cyanopropyl/ - cyclopenta /f/ /1/ benzopyrans and the preparation thereof | |
GB1439093A (en) | Process for the preparation of 5-nitronaphthoquinone-1,4 | |
GB1492525A (en) | Cyclic alkanones | |
SE7507318L (en) | PROCEDURE FOR THE PRODUCTION OF AROMATIC URETANES. | |
GB1176248A (en) | Novel 13-Alkyl-Des-A-10-Aza-Gonenes and Processes for Preparing Hexahydroindanes therefrom | |
EP0109817A3 (en) | Process for preparing oxazolinoazetidinones | |
GB1398314A (en) | Process for the manufacture of hexahydroindane-4-carboxylic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PLNP | Patent lapsed through nonpayment of renewal fees |